AstraZeneca’s AZD1222 vaccine has driven the UK’s response to the Covid-19 pandemic. Over 54 million doses of the vaccine, developed in tandem with researchers at Oxford University have been supplied to the UK since it was approved in December 2020, making it the most common vaccine in the UK by a considerable margin.
The vaccine has been extremely successful and has been produced at cost. However it has also required the Cambridge-headquartered company to recruit an army of specialist staff – a task made even more difficult by the restrictions of remote working.
In this case study, Maggie Spong, AstraZeneca’s vice president talent acquisition, explains how she and her colleagues have met this challenge – and how they have used this extraordinary situation as an opportunity to promote diversity throughout the company.